Concepedia

Joseph Woolery

JW

Statistics

Publications

8

Citations

1.2K

H-Index

8

Active since

2011

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Tennessee Oncology

Sarah Cannon

Zymeworks (Canada)

Seoul National University Bundang Hospital

Joseph Woolery is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacology.

Publications per year

2011–2022

8

Publications

8

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

, , +12

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton et al. · The Lancet Oncology · 2022 · 182 citations · Full text

, , +17

Update on aurora kinase targeted therapeutics in oncology

Myke R. Green, Joseph Woolery, Daruka Mahadevan · Expert Opinion on Drug Discovery · 2011 · 74 citations · Full text

, , +15

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

Funda Meric‐Bernstam, Diana L. Hanna, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2021 · 68 citations

, , +15

460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

Komal Jhaveri, Hyo S. Han, Efrat Dotan et al. · Annals of Oncology · 2022 · 54 citations · Full text

, , +17

1–5 of 8